Introduction And Genetics
Wiskott-Aldrich syndrome is an X-linked recessive combined immunodeficiency disorder. It primarily affects males and manifests with a classic clinical triad.
| Classic Triad of Wiskott-Aldrich Syndrome |
|---|
| Thrombocytopenia with small platelets |
| Atopic dermatitis (Eczema) |
| Susceptibility to recurrent infections |
The disease is caused by pathogenic variants in the WASP gene.
Pathophysiology
- The WASP gene encodes the Wiskott-Aldrich syndrome protein.
- This protein controls the assembly of actin filaments.
- Actin filaments are required for normal cell migration and cell-cell interactions.
- T cells in affected patients lack the markedly fimbriated surface seen in normal T cells under electron microscopy.
- The primary immunologic defect appears to be the inability of T cells to provide adequate help to B cells.
- This leads to an impaired humoral immune response, especially to polysaccharide antigens.
Clinical Manifestations
Patients present with multi-system involvement early in life.
Bleeding Diathesis
- Bleeding is often the earliest clinical manifestation.
- Infants commonly present with prolonged bleeding from the circumcision site.
- Bloody diarrhea is another frequent presentation during infancy.
Immunodeficiency And Infections
- Recurrent infections typically develop during the first year of life.
- Patients are highly susceptible to encapsulated bacteria.
- Common pathogens include Streptococcus pneumoniae and Haemophilus influenzae.
- These organisms cause otitis media, pneumonia, meningitis, and sepsis.
- As the child grows older, infections with opportunistic agents occur.
- Pneumocystis jirovecii and various herpesviruses become frequent pathogens.
Dermatologic And Autoimmune Features
- Atopic dermatitis usually develops in the first year of life.
- Autoimmunity can occur as the disease progresses.
- Hemolytic anemia and arthritis are commonly associated autoimmune conditions.
Malignancy Risk
- Patients have a high susceptibility to lymphoreticular malignancies.
- Epstein-Barr virus (EBV) associated malignancies are a major cause of death.
Laboratory Diagnosis
Diagnosis is established by evaluating the hemogram, immunoglobulin levels, and cellular immune function.
| Investigation | Characteristic Findings |
|---|---|
| Complete Blood Count | Thrombocytopenia (<80,000/μL) is present. Platelets are characteristically small in size (low mean platelet volume). Eosinophilia is common. |
| Bone Marrow | Normal-appearing megakaryocytes are seen despite peripheral thrombocytopenia. |
| Cellular Immunity | T cell percentages are moderately reduced. Lymphocyte responses to mitogens are variably depressed. |
| Specific Antibodies | Absent or greatly diminished isohemagglutinins. Poor antibody responses after immunization with polysaccharide vaccines. |
Immunoglobulin Profile
The serum immunoglobulin pattern in WAS is distinct and helps in diagnosis.
| Immunoglobulin Class | Serum Level |
|---|---|
| IgM | Low |
| IgG | Normal or slightly low |
| IgA | Elevated |
| IgE | Elevated |
Management
Management involves aggressive supportive care, infection prophylaxis, and definitive cellular therapies.
Supportive And Medical Care
- Good supportive care includes appropriate nutrition and aggressive management of eczema and cutaneous infections.
- Immunoglobulin replacement therapy is strictly indicated due to profound antibody deficiency.
- This is required regardless of the patient's serum immunoglobulin levels.
- Only killed vaccines should be administered to these patients.
- Antimicrobial prophylaxis against Pneumocystis jirovecii and herpes simplex virus is often recommended.
- Splenectomy may be necessary for severe and refractory thrombocytopenia.
- Post-splenectomy patients strictly require lifelong penicillin prophylaxis against encapsulated organisms.
Definitive Therapies
| Therapy Type | Details |
|---|---|
| Hematopoietic Stem Cell Transplantation (HSCT) | This is the treatment of choice when a high-quality matched donor is available. It is usually curative and offers the best long-term survival. |
| Gene Therapy | Used in select cases. It has shown sustained benefits in several patients. However, early trials were associated with the development of malignancies. |